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Carotid Body Denervation
Too Soon to Get Breathless
About Heart Failure?*
Blair D. Johnson, PHD, Michael J. Joyner, MD
Rochester, Minnesota
The carotid body chemoreceptors are the primary oxygen
sensors in both humans and mammals (1). When arterial
oxygen (O2) levels fall, they evoke a rise in minute ventila-
tion that mirrors the O2 hemoglobin dissociation curve.
When activated, they also evoke large increases in efferent
sympathetic nerve activity (2). For many years, these phys-
iological responses were thought to be mediated almost
exclusively by arterial O2 partial pressure. Starting in the
1960s, carotid body ablation in humans was used as an
experimental treatment for bronchial asthma and chronic
obstructive pulmonary disease, but the procedure failed to
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produce signiﬁcant beneﬁts for patients. Recent evidence
has emerged in animal models of congestive heart failure
(CHF), demonstrating that chronic reductions in carotid body
blood ﬂowmight sensitize the chemoreceptors to increase both
their tonic activity and responses to hypoxia (3). In this context,
at least some CHF patients have augmented ventilatory
responses to hypoxia, showing that this phenomenon occurs in
humanswithCHF (4). The question then is does the enhanced
activity of the carotid bodies contribute to the various forms of
dyspnea and devastating sympathoexcitation seen in CHF (5)?
In this issue of the Journal, Del Rio et al. (6) induced
myocardial infarction and subsequent CHF in rats and
denervated the carotid bodies after the infarction in some of
the animals. They found a host of improvements in auto-
nomic, cardiac, and respiratory function and an improved
survival rate 14 weeks after denervation when compared with
CHF control subjects. These ﬁndings underscore the idea
that the carotid bodies become overactive and contribute to
the pathophysiology of CHF. The results of this study also
raise several key ideas that are relevant to the treatment of
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Some beneﬁts of CBD might be similar to exercise training
in CHF (Fig. 1). Both might have similar effects on sympa-
thetic activity. Exercise training in human (7) and animal (8)
CHF models reduces sympathetic nerve activity to values
observed in normal control subjects. Along these lines, Del Rio
et al. (6) found thatCBDrestores the low-frequency component
of systolic blood pressure variability (estimate of sympathetic
tone to the vasculature) to values obtained by normal sham-
operated rats. Similarly, both exercise training (9) and CBD
improve cardiac vagal activity by augmenting the high-frequency
component of heart rate variability. Baroreﬂex function also
seems to be restored after exercise training (10) or CBD.
Therefore, autonomic function is improved by both therapies.
Additionally, both therapies positively impact cardiac remodel-
ing (11) and normalize breathing patterns (12) after myocardial
infarction. Like CBD in rats, exercise training in humans with
CHF can also improvemortality (13). A critical question is does
exercise training normalize carotid body responses in CHF
patients? And if this occurs, does it play a role in the positive
effects of training on sympathoexcitation in CHF?
Despite the potential similarities between exercise training
and CBD on sympathetic outﬂow in CHF, it is unlikely
that CBD provides similar widespread physiological gains
achieved by exercise training in CHF (Fig. 1). These include
improved exercise tolerance, endothelial function, peripheral
blood ﬂow, and various metabolic parameters. Further-
more, exercise training reduces CHF-related hospital visits
(14). Although CBD seems tempting as a therapeutic tool
in humans to improve CHF-related pathophysiology, we
currently can only speculate about all the relevant physio-
logical beneﬁts/side effects that might be achieved or
encountered in human trials with this therapy.
The CBD data from Del Rio et al. (6), along with the
exercise training data noted in the preceding text, are consistent
with ideas that sympathoinhibitory therapeutic strategies are
critical in CHF. In this context, a notable success in the
treatment of CHF has been the widespread adoption of
beta-blocker therapy. There were hints that this therapy might
be effective as early as the middle 1970s, but for a variety
of reasons, it was not widely adopted until much later
(15). More recent approaches to pharmacological sym-
pathoinhibition with drugs like moxonidine have been less
promising (16). However, the beta-blocker data, plus earlier
data from hypertension trials, have shown that sympatholytic
therapy is highly effective in reducing mortality (17). Along
these lines, there is at least some evidence in the hypertension
literature indicating that reﬂex increases in sympathetic outﬂow
associated with lowering blood pressure might offset some of
the mortality beneﬁt associated with the lower pressure (18).
That said, do we need new and improved sympathoinhibitory
drugs? In addition to being beneﬁcial for classic CHF, would
they be useful for the current wave of obesity-driven “resistant”
hypertension that seems to be associated with high levels of
sympathetic activity? Would they also be useful in the
Figure 1 Exercise Training and Carotid Body Denervation
A summary of the beneﬁts associated with chronic exercise training in congestive heart failure (CHF) patients, and the overlap of the beneﬁts observed by Del Rio et al. (6) after
carotid body denervation in CHF rats. Although some of these parameters have yet to be explored after carotid body denervation, exercise training seems to offer a greater
number of independent beneﬁts.
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2432treatment of the emerging epidemic of diastolic dys-
function? Have we moved away from more renal-centric views
of peripheral vasoconstriction to more central sympathetically
driven mechanisms that require new treatment options (19)?
Along these lines, sympatholytic device-based treatment for
resistant hypertension has shown some promise, and there is
discussion about its potential utility in CHF (16).
The ﬁndings by Del Rio et al. (6) are likely to increase
enthusiasm for CBD as a possible therapeutic strategy in
CHF as well as hypertension (20). However, is this war-
ranted? The many potential consequences of CBD need to
be addressed to ensure patient safety when performing nor-
mal activities (e.g., riding on a plane, traveling to altitude),
considering the central role that the carotid body chemore-
ceptors play in maintaining arterial O2 saturation during
these challenges. Furthermore, patients with CHF have
a number of comorbidities, such as respiratory diseases and
obstructive sleep apnea, and CBD might worsen these
conditions. Finally, ablation of the carotid body chemore-
ceptors might pose risks, including concurrent baroreceptor
failure (21). All of these potential limitations need to be
carefully considered before the carotid bodies become rou-
tine therapeutic targets in diseases like CHF that are as-
sociated with sympathoexcitation. More importantly, the
search for sympatholytic therapies needs to be expanded while
exercise training should continue to be prescribed.
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